Cargando…

Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha

INTRODUCTION: Despite the recent approval of several therapies in the adjuvant setting of melanoma, tumor relapse still occurs in a significant number of completely resected stage III-IV patients. In this context, the use of cancer vaccines is still relevant and may increase the response to immune c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moschella, Federica, Buccione, Carla, Ruspantini, Irene, Castiello, Luciano, Rozo Gonzalez, Andrea, Iacobone, Floriana, Ferraresi, Virginia, Palermo, Belinda, Nisticò, Paola, Belardelli, Filippo, Proietti, Enrico, Macchia, Iole, Urbani, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233106/ https://www.ncbi.nlm.nih.gov/pubmed/37274275 http://dx.doi.org/10.3389/fonc.2023.1145667

Ejemplares similares

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study
por: Urbani, Francesca, et al.
Publicado: (2020)

Corrigendum to “Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring”
por: Macchia, Iole, et al.
Publicado: (2020)

Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring
por: Macchia, Iole, et al.
Publicado: (2020)

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma
por: Rozera, Carmela, et al.
Publicado: (2015)

Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications
por: Aricò, Eleonora, et al.
Publicado: (2019)

Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
por: Aricò, Eleonora, et al.
Publicado: (2020)

Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays
por: Macchia, Iole, et al.
Publicado: (2013)

Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19
por: Aricò, Eleonora, et al.
Publicado: (2022)

Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments
por: Aricò, Eleonora, et al.
Publicado: (2011)

In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
por: Castiello, Luciano, et al.
Publicado: (2019)

Type I Interferons as Joint Regulators of Tumor Growth and Obesity
por: Gessani, Sandra, et al.
Publicado: (2021)

Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients
por: Palermo, Belinda, et al.
Publicado: (2018)

Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS
por: Franzese, Ornella, et al.
Publicado: (2016)

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial
por: Aricò, Eleonora, et al.
Publicado: (2021)

Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use
por: Antonelli, Guido, et al.
Publicado: (2015)

Type I Interferons as Regulators of Human Antigen Presenting Cell Functions
por: Gessani, Sandra, et al.
Publicado: (2014)

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade
por: Rossi, Alessandra, et al.
Publicado: (2020)

Eosinophils as potential biomarkers in respiratory viral infections
por: Macchia, Iole, et al.
Publicado: (2023)

Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
por: Galli, Filippo, et al.
Publicado: (2020)

Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients
por: Palermo, Belinda, et al.
Publicado: (2023)

Interferon-α-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12
por: Santini, Stefano M., et al.
Publicado: (2011)

Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers
por: Trono, Paola, et al.
Publicado: (2017)

Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice
por: Santini, Stefano M., et al.
Publicado: (2000)

ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8α(+) Dendritic Cells
por: Schiavoni, Giovanna, et al.
Publicado: (2002)

The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy
por: Ziccheddu, Giovanna, et al.
Publicado: (2013)

Immunomodulators: interleukins, interferons, and IV immunoglobulin
por: Roelofs, Joris J., et al.
Publicado: (2008)

T-cell repertoire diversity: friend or foe for protective antitumor response?
por: Porciello, Nicla, et al.
Publicado: (2022)

Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
por: Gessani, Sandra, et al.
Publicado: (2019)

Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis
por: Aricò, Eleonora, et al.
Publicado: (2016)

Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients
por: Serana, Federico, et al.
Publicado: (2009)

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
por: Kamm, Christian Philipp, et al.
Publicado: (2012)

miR-181c associates with tumor relapse of high grade osteosarcoma
por: Federica, Mori, et al.
Publicado: (2015)

Interferon Regulatory Factor 8-Deficiency Determines Massive Neutrophil Recruitment but T Cell Defect in Fast Growing Granulomas during Tuberculosis
por: Rocca, Stefano, et al.
Publicado: (2013)

Correction: Interferon Regulatory Factor 8-Deficiency Determines Massive Neutrophil Recruitment but T Cell Defect in Fast Growing Granulomas during Tuberculosis
por: Rocca, Stefano, et al.
Publicado: (2013)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
por: Magenau, John M., et al.
Publicado: (2021)

Type I Interferons in COVID-19 Pathogenesis
por: Palermo, Enrico, et al.
Publicado: (2021)

Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection
por: Cacopardo, Bruno, et al.
Publicado: (2012)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients
por: Atzpodien, J, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_9t79sski3dqcfdj1pl74q6qvar